{"company":{"id":3780390,"name":"Senti Bio","domain":"sentibio.com","url":"https://alion.io/company/sentibio"},"section":"news","answer":"Senti Bio: 18 headlines on record, 0 headlines in the last 90 days. Its story counts 4 milestones.","figures":[{"label":"Headlines","value":"18"},{"label":"In 90 days","value":"0"},{"label":"Milestones","value":"4"}],"blocks":[{"key":"news","title":"Headlines","source":"the outlets named on each headline, each story once","rows":17},{"key":"story","title":"Milestones","source":"Each milestone is dated by its source: registers, filings, the press","rows":4}],"news":[{"date":"2026-03-27","kind":"Press release","title":"Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update","source":"The Manila Times","url":"https://manilatimes.net/2026/03/27/tmt-newswire/globenewswire/senti-bio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-corporate-update/2309301"},{"date":"2025-12-08","kind":"Blog","title":"Promising results from an ongoing Phase I multicenter study of SENTI-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf logic gated CAR NK cell therapy in adults with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)","url":"https://sentibio.com/promising-results-from-an-ongoing-phase-i-multicenter-study-of-senti-202-a-first-in-class-cd33-and-or-flt3-not-endomucin-emcn-selective-off-the-shelf-logic-gated-car-nk-cell-therapy-in-adul/"},{"date":"2025-12-08","kind":"Blog","title":"Correlative data from an ongoing Phase 1, multicenter study of SENTI-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf CAR NK cell therapy for Acute Myeloid Leukemia (AML) is consistent with its clinical activity and unique logic gated mechanism of action","url":"https://sentibio.com/correlative-data-from-an-ongoing-phase-1-multicenter-study-of-senti-202-a-first-in-class-cd33-and-or-flt3-not-endomucin-emcn-selective-off-the-shelf-car-nk-cell-therapy-for-acute-myeloid-l/"},{"date":"2025-11-03","kind":"Press release","title":"Senti Bio to Present Updated Clinical Results of First-in-Class Logic Gated CD33/FLT3 Cell Therapy, SENTI-202, at the American Society of Hematology (ASH) Annual Meeting 2025","source":"The Globe and Mail","url":"https://theglobeandmail.com/investing/markets/stocks/SNTI/pressreleases/35864551/senti-bio-to-present-updated-clinical-results-of-first-in-class-logic-gated-cd33flt3-cell-therapy-senti-202-at-the-american-society-of-hematology-ash-annual-meeting-2025/"},{"date":"2025-07-21","kind":"News","title":"Senti Bio's Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum","source":"YahooFinance","url":"https://finance.yahoo.com/news/senti-bio-chief-medical-officer-125500396.html"},{"date":"2025-07-18","kind":"Blog","title":"Bryan Baum","url":"https://sentibio.com/bryan-baum/"},{"date":"2025-04-30","kind":"Blog","title":"SENTI-202 CD33 OR FLT3 NOT EMCN Logic-Gated Gene Circuit Components Selectively Target AML while Protecting Human HSC/HPCs from Off-Tumor Toxicity in a Humanized Mouse Model","url":"https://sentibio.com/senti-202-cd33-or-flt3-not-emcn-logic-gated-gene-circuit-components-selectively-target-aml-while-protecting-human-hsc-hpcs-from-off-tumor-toxicity-in-a-humanized-mouse-model/"},{"date":"2025-04-29","kind":"Blog","title":"First-In-Human, Multicenter Study of SENTI-202, a CD33/FLT3 Selective Off-the-Shelf Logic Gated CAR NK Cell Therapy in Hematologic Malignancies including AML: Correlative Data","url":"https://sentibio.com/first-in-human-multicenter-study-of-senti-202-a-cd33-flt3-selective-off-the-shelf-logic-gated-car-nk-cell-therapy-in-hematologic-malignancies-including-aml-correlative-data/"},{"date":"2025-04-28","kind":"Press release","title":"Senti Bio's SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML","source":"Nasdaq","url":"https://nasdaq.com/press-release/senti-bios-senti-202-first-class-shelf-logic-gated-selective-cd33-or-flt3-not-emcn"},{"date":"2025-04-03","kind":"News","title":"Senti Bio to Showcase SENTI-202 Clinical Data and Novel Logic Gated Gene Circuit Mechanism of Action in Oral and Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025 (2025-04-03)","source":"SeekingAlpha","url":"https://seekingalpha.com/pr/20056215-senti-bio-to-showcase-sentiminus-202-clinical-data-and-novel-logic-gated-gene-circuit"},{"date":"2025-03-19","kind":"Blog","title":"Feng Hsiung","url":"https://sentibio.com/feng-hsiung/"},{"date":"2025-03-12","kind":"Press release","title":"Senti Bio Appoints Feng Hsiung to Board of Directors","source":"The National Law Review","url":"https://natlawreview.com/press-releases/senti-bio-appoints-feng-hsiung-board-directors"},{"date":"2025-02-25","kind":"Blog","title":"Faraz Siddiqui","url":"https://sentibio.com/faraz-siddiqui/"},{"date":"2025-01-07","kind":"Blog","title":"Donald Tang","url":"https://sentibio.com/donald-tang/"},{"date":"2024-12-02","kind":"Blog","title":"Fran Schulz","url":"https://sentibio.com/fran-schulz/"},{"date":"2024-05-13","kind":"Press release","title":"Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia","source":"Nasdaq","url":"https://nasdaq.com/press-release/senti-bio-announces-first-patient-dosed-in-phase-1-clinical-trial-of-senti-202-for"},{"date":"2024-04-30","kind":"News","title":"Star Tribune","source":"Star Tribune","url":"https://markets.financialcontent.com/startribune/article/gnwcq-2024-4-30-senti-bio-announces-publication-of-senti-202-preclinical-data-demonstrating-potential-of-logic-gated-car-nk-cell-therapy-for-the-treatment-of-acute-myeloid-leukemia-aml"}],"story":[{"title":"Board appointment Senti Bio Appoints Feng Hsiung to Board of Directors · The National Law Review","url":"https://natlawreview.com/press-releases/senti-bio-appoints-feng-hsiung-board-directors"},{"title":"Won a grant $2M · CORDIS","url":"https://www.sbir.gov/awards?keywords=75N91021C00026"},{"title":"Won a grant $225k · CORDIS","url":"https://www.sbir.gov/awards?keywords=1R43DK117752-01A1"},{"title":"Won a grant $225k · CORDIS","url":"https://www.sbir.gov/awards?keywords=1747250"}],"as_of":"2026-11-16","cite":"Senti Bio, News. Alion, Nov 16, 2026. https://alion.io/company/sentibio/news","html_url":"https://alion.io/company/sentibio/news","json_url":"https://alion.io/company/sentibio/news.json","license":"CC BY-SA 4.0","meta":{"source":"Alion","generated_at":"2026-11-16T07:10:23Z"}}